cyrilzakka/clinical-trials huggingface dataset:
Knowledge of Vital Pulp Therapy in Permanent Teeth After Educational Programme: A Before and After Study

evaluating the extent of knowledge of vital pulp therapy in permanent dentition among a group of dental interns in Egypt after educational programme.

evaluating the extent of knowledge of vital pulp therapy in permanent dentition using a survey among a group of dental interns in Egypt after educational programme.

Eligibility Criteria:
Inclusion Criteria:

* Dental interns enrolled in the Pediatric Dentistry Department, Cairo University .
* Candidates who are willing to participate

Exclusion Criteria:

* Responses with incomplete information
Patient Experiences with the COVID-19 Vaccination After Breast Cancer Treatment

This study aims to elicit patient experiences, choices, and side effects associated with the COVID-19 vaccine after breast cancer surgery. Lymph node swelling is a known and common side effect of both the Moderna and Pfizer COVID-19 vaccines. This is the body's normal reaction to the vaccine. It is worrisome that lymph node swelling after the vaccine mimics that found in breast cancer which has spread to the lymph nodes. This side effect will cause worry and anxiety amongst patients as a result. For patients who have had lymph node removal (axillary lymph node dissection or sentinel lymph node biopsy) and are at risk of lymphedema, the investigators are concerned that the lymph node swelling may tax the lymphatic system and incite lymphedema in those at risk or worsen it in those with BCRL. Fear of lymphedema is high in this population and the investigators need to better understand what risk, if any, lymph node swelling after the COVID-19 vaccine imparts to BCRL risk.

* Hypothesis 1: Patients will choose to receive the vaccine on the arm contralateral to axillary lymph node removal, or in the lower extremity if they have had bilateral axillary lymph node removal
* Hypothesis 2: Patients with a history of breast cancer will experience axillary lymph node swelling after receiving the COVID-19 vaccine at the same rate as the general population
* Hypothesis 3: Patients with axillary surgery who develop lymph nodes swelling in the ipsilateral side might be at increased risk of developing lymphedema

Eligibility Criteria:
Inclusion Criteria:

* Female patients who are
* ≥18 years of age and have a
* History of breast cancer For the MGH site, patients must have
* Received some breast cancer treatment at MGH or its affiliates
* Received perometry measurements to measure arm volume at MGH

Exclusion Criteria:

* None
Treatment of Acute Sinusitis With High-Dose vs. Standard-Dose Amoxicillin/Clavulanate

Comparative-effectiveness study of the treatment of acute bacterial sinusitis with amoxicillin/clavulanate 875mg/125mg bid for 7 days with or without the addition of immediate-release amoxicillin 875 mg bid x 7 days. .

Double-blind comparative-effectiveness study of the treatment of acute bacterial sinusitis with standard dose of amoxicillin/clavulanate 875mg/125mg bid for 7 days, as recommended by the Infectious Disease Society of America, with or without the addition of immediate-release amoxicillin 875 mg bid x 7 days. The study aims are 1) to confirm, or not, our recent findings of more rapid improvement in overall symptoms with the additional amoxicillin, but also of more frequent diarrhea and vaginal yeast infections and 2) to assess, from the participants' point of view, the balance between improvement and adverse effects.

Eligibility Criteria:
Inclusion Criteria:

1. Adults 18 and older who are patients at the Albany Medical Center Internal Medicine and Pediatrics practice (study site).
2. Clinical diagnosis of acute bacterial sinusitis in accordance with the guidelines of the Infectious Disease Society of America (fitting into one of 3 categories: persistent sinus symptoms for 10 days or more; severe sinus symptoms for 3 days or more; or worsening sinus symptoms after initial improvement (double sickening).

Exclusion Criteria:

1. Previous enrollment in the current study
2. Allergy or intolerance to any penicillin or to amoxicillin/clavulanate
3. Serious hypersensitivity reaction to any beta lactam
4. Elevated risk of amoxicillin-resistant bacteria: a. amoxicillin, penicillin, or other beta-lactam within the past month; b. known to have had methicillin-resistant Staph aureus
5. Chronic or recurrent "sinus" problems (defined as a) persistent symptoms of "sinus" congestion, not attributed to nasal allergies, for 8 weeks or more or b) 2 or more episodes of antibiotic-treated "sinusitis" in past 3 months
6. Need to use high-dose amoxicillin/clavulanate or levofloxacin or to send to emergency department or to hospitalize because of a) signs of severe infection or b) immunocompromise
7. Cognitive impairment, so unable to give reliable symptom ratings (even if a health proxy can give consent)
8. Pregnant women and nursing mothers
9. Drug warnings: a) taking allopurinol; b) current mononucleosis; c) chronic kidney disease stage 4 (estimated glomerular filtration rate \<30); d) hepatic impairment (not including isolated transaminase elevated \< 2 times upper limit of normal); e) history of antibiotic-associated colitis (C. difficile)
5-HTP in Patients With IBD in Clinical and Biologic Remission:Effect on Fatigue Scores

This placebo cross-over trial aims to study the effect of the oral intake of an essential amino-acid 5-OH tryptophan, the precursor of serotonin, on the fatigue scores in IBD patients in deep clinical and biological remission.


Eligibility Criteria:
Inclusion Criteria:

* The subject is male or female and aged 18 to 60 yrs (inclusive)
* The subject has a documented Crohn's disease or ulcerative colitis
* The subject is, in the opinion of the investigator, capable of understanding and complying protocol requirements
* The subject is in clinical remission over last 3 months (based on physician global assessment)
* The subject is in clinical remission at day 0 based on validated scores (SCCAI ≤ 2 for ulcerative colitis or Harvey Bradshaw index ≤ 4 for Crohn's disease).
* The subject reports fatigue on a quantified scale (visual analogue scale 0 - 10) of 5 or more
* The subject is treated with biologicals and/or immunosuppressives since at least 6 months with stable dose over last 3 months
* The subject is in biologic remission at day 0: CRP \< 10 mg/l and faecal calprotectin value \< 250 mg/kg

Exclusion Criteria:

* The subject has a clinical validated depression
* The subject is taking antidepressives or neuroleptics
* The subject has a psychiatric comorbidity
* The subject has important comorbidities: cardiovascular disease, obstructive lung pathology, neoplasia or other
* The subject has a documented Anemia (based on lab results including Hb \< 12-13 g/dl respectively for saturation index \< 20%, Vit B12 \< 148 pmol/L or folic acid \< 6 nmol/L)
* The subject has a documented hypothyreoidea (documented by a recent lab result including TSH)
* The subject reports an infection within 2 weeks before inclusion
* The subject reports any change in IBD medication (biologicals and immunosuppressives) in the last 12 weeks before inclusion
* The subject was treated with oral corticosteroids during the last 8 weeks before enrolment
* The subject reports an ongoing pregnancy or breastfeeding
* The subject has a history of lymphoproliferative disease or cancer other than basocellular skin cancer
* The subject underwent surgery in the past 12 weeks prior to the screening visit
* The subject reports a history of clinically significant drug abuse (defined as any illicit drug use) or alcohol abuse within 1 year prior to inclusion
Effects of Gait Training With and Without PNF on Balance ,Gait and Activities of Daily Living in Parkinson's Patients

Proprioceptive Neuromuscular Facilitation (PNF) and gait training exercises are specifically used to treat balance, gait and functional activities in Parkinson s patients. PNF has been compared with gait training and balance training in other conditions like stroke and multiple sclerosis but limited literatures are present in which PNF has been compared with gait training in Parkinson patients.


Eligibility Criteria:
Inclusion Criteria:

* Parkinson's patients.
* Patients from both gender around the age of 45-65.
* Patient with a score of 42 above on the Berg Balance Scale.
* Patients with shuffling gait
* Patient with good cognitive function minimum score of 20 or more on Mini-mental Status Examination MMSE scale
* Exclusion Criteria:
* Patients with a history of CVA.
* Patient with peripheral vascular disease.
* Patient with fracture or dislocation of lower limb.
* Patient with peripheral nerve injury
Preoperative vs. Postoperative Misoprostol in Elective Cesarean Section

This prospective double-blind placebo-controlled randomized clinical trial will be conducted at Ain-Shams University Maternity Hospital from April 2017 till October 2017. 120 women candidate foe elective cesarean section will receive preoperative sublingual 400 microgram of misoprostol, and another 120 women will receive postoperative sublingual 400 microgram of misoprostol.


Eligibility Criteria:
Inclusion Criteria:

* Patients booked for elective cesarean section.
* Singleton pregnancies.
* Full term pregnancies (GA 37- 42 Wks).
* Age (18-40 yrs).
* body mass index (BMI) (20-30(Kg/m2 .

Exclusion Criteria:

* Contraindication to spinal anesthesia.
* Blood dyscrasias.
* Large fibroids.
* Multiple pregnancies.
* Overdistended uterus eg. Hydramnios.
* Pre-eclampsia.
* Marked maternal anemia (Preoperative hemoglobin \< 9 gm/dl).
* Previous history of PPH.
* Contraindications to prostaglandin therapy (e.g. history of severe bronchial asthma or allergy to misoprostol.
* Placenta previa.
* Previous myomectomy.
* Extreme of BMI (\<20 or \>30 Kg/m2 ).
Sarpogrelate Drug Interaction

This is a randomized, open-label, single \& multiple-dose, three-sequence, three-period crossover study to investigate the effect of sarpogrelate hydrochloride on the disposition of metoprolol tartrate in healthy male volunteers

Eligibility for participation of this study will be determined from demographic information, medical history, physical examination, electrocardiogram (ECG) and clinical laboratory tests within 4 weeks before study drug administration. Subjects suitable for this study will be admitted to the Clinical Trial Center of Ajou University Medical Center on the day before dosing (Day -1).

On Day 1, Subjects will be dosed study drug (metoprolol tartrate 100 mg once a day only, or metoprolol tartrate 100 mg once a day with sarpogrelate hydrochloride 100 mg three times a day, sarpogrelate hydrochloride 100 mg three times a day pretreatment for three days and metoprolol tartrate 100 mg once a day with sarpogrelate hydrochloride 100 mg three times a day).

Pharmacokinetic samplings and blood pressure/pulse rate measurement will be done upto 12 hours after metoprolol tartrate 100 mg dosing.

After one week of washout period (Day 8), Subjects will be dosed study drug by crossover manner, and pharmacokinetic samplings and blood pressure/pulse rate measurement will be done upto 12 hours after metoprolol tartrate 100 mg dosing.

After one week of washout period (Day 15), Subjects will be dosed study drug by crossover manner, and pharmacokinetic samplings and blood pressure/pulse rate measurement will be done upto 12 hours after metoprolol tartrate 100 mg dosing.

Eligibility Criteria:
Inclusion Criteria:

* Healthy male subjects aged 20 - 45 years
* With in 20% of ideal body weight, {Ideal body weight=\[height(cm)-100\]\*0.9}
* Agreement with written informed consent

Exclusion Criteria:

* Clinically significant cardiovascular, pulmonary, hepatic, renal, hematologic, gastrointestinal disease or mental disorder (Past history or present)
* Inadequate result of laboratory test (especially, AST/ALT \> 1.25 x UNL, Total bilirubin \> 1.5 x UNL)
* Positive reaction in the HBs Ag, anti-HCV Ab, anti-HIV Ab, VDRL test
* Taking OTC(Over the counter)medicine including oriental medicine within 7 days
* Clinically significant allergic disease (Except for mild allergic rhinitis and dermatitis seems to be not need for medication)
* Subject with known for hypersensitivity reaction to Metoprolol or Sarpogrelate
* Previous whole blood donation within 60 days or component blood donation within 30 days
* Previous participation of other trial within 90 days
* Continued taking caffeine (caffeine \> 5 cup/day), drinking (alcohol \> 30 g/day) and severe heavy smoker (cigarette \> 1/2 pack per day)
* An impossible one who participates in clinical trial by investigator's decision including for reason of laboratory test result
Comparative Effectiveness of Readmission Reduction Interventions for Individuals with Sepsis or Pneumonia

An adaptive platform trial to compare effectiveness of different care models to prevent readmissions for patients hospitalized with sepsis or lower respiratory tract infection. The primary outcome is number of days spent at home within 90 days after hospital discharge.

This study implements an adaptive platform trial to compare effectiveness of different care models to prevent readmissions for patients hospitalized with sepsis or lower respiratory tract infection and discharged to home (with or without a short stay in a skilled nursing facility prior to going home): structured telephone support (STS); low-intensity remote patient monitoring (RPM-Low); and high-intensity remote patient monitoring (RPM-High). The remote patient monitoring models will be staffed by a physician or a nurse (Standard Team) or by a dedicated nurse-practitioner (NP)-led multidisciplinary team (Enhanced Team). Patients will be randomized to one of five arms: STS, RPM-Low + Standard Team, RPM-Low + Enhanced Team, RPM-High + Standard Team, and RPM-High + Enhanced Team. Using response adaptive randomization (RAR), interim outcome results will be used to modify the random allocation of patients to each study arm. The primary outcome is number of days spent at home within 90 days after hospital discharge. Patient-reported functional status and quality of life data will be collected in addition to electronic health record (EHR) and claims-based data to measure health care utilization. Qualitative interviews with patients and providers will provide insight into the effectiveness of the implementation process.

Eligibility Criteria:
Inclusion Criteria:

* UPMC Health Plan members
* Medicare Fee-for-Service enrollees
* Age 21+ -Hospitalized with a primary diagnosis of sepsis or lower respiratory tract infection, --
* Discharged to home, independent living facility, or skilled nursing facility
* Readmission risk is moderate or high

Exclusion Criteria:

* Admitted from hospice;
* Discharged to hospice, inpatient rehabilitation, or a long term acute care facility;
* Known to be pregnant;
* Current enrollment in another remote patient monitoring program;
* Failure of the Callahan 6 item cognitive screen and do not have a proxy to consent;
* No access to a technological device required to participate in remote patient monitoring program;
* Current enrollment in UPMC Advanced Illness Care program;
* Severe, persistent cognitive impairment;
* No documented PCP;
* PCP disapproves of the patient being enrolled in remote patient monitoring;
* Discharged from hospital to skilled nursing facility and stay at the skilled nursing facility for greater than 28 days
Smoking Cessation for Depression and Anxiety Treatment

The primary aim of this research study is to enhance smoking cessation outcome among smokers with elevated anxiety and depression. We are comparing two group treatment approaches: (1) An educational-supportive psychotherapy and standard smoking cessation treatment, and (2) An integrated smoking cessation, and anxiety and depression management treatment program (SDAT). Both treatments also utilize nicotine replacement therapy.


Eligibility Criteria:
Inclusion Criteria:

* Ages 18-65 years old
* Capable of providing informed consent
* Willing to attend all study visits and comply with the protocol
* Daily smoker for at least one year
* Currently smoke an average of at least 6 cigarettes per day
* Report a motivation to quit smoking in the next 6 weeks of at least 5 on a 10-point scale
* Elevated anxiety or depression

Exclusion Criteria:

* Use of other tobacco products
* Current or past psychotic disorders of any type, or comorbid psychiatric conditions that are relative or absolute contraindications to the use of any treatment option in the study protocol
* Currently suicidal or high suicide risk
* Current use of any pharmacotherapy or psychotherapy for smoking cessation not provided by the researchers during the quit attempt
* Concurrent psychotherapy initiated within three months of baseline, or ongoing psychotherapy of any duration directed specifically toward the treatment of anxiety or depression
* Current or intended participation in a concurrent substance abuse treatment
* Current non-nicotine substance dependence
* Insufficient command of English to participate in assessment or treatment
Long-term Safety Follow-up in Recipients Who Previously Received Medeor's Cellular Immunotherapy Products

At the completion of primary follow-up of various Medeor Transplant studies (called parent studies), subjects receiving Medeor's cellular immunotherapy products will be followed annually for up to an additional 84 months (7 years), in order to evaluate for long-term safety.

Study MDR-105-SAE is intended to be the long-term safety monitoring extension of Medeor's cellular immunotherapy, kidney transplant clinical studies. This Master Protocol has been created in order to establish a single database for all long-term safety data for those subjects that have received Medeor's cellular products. This Master Protocol will provide up to 84 months (7 years) of additional follow-up.

Long-term safety of subjects treated with Medeor's cellular immunotherapy has not been assessed. This study will collect the data into a centralized database allowing for continuous monitoring of any important safety signals.

Eligibility Criteria:
Inclusion Criteria:

1. Able and willing to fully comply with all study procedures and restrictions.
2. Able to understand and provide written, signed, and dated informed consent to participate in the study in accordance with ICH GCP Guideline and all applicable local regulations.
3. Have previously completed a Medeor study and received a Medeor cellular immunotherapy product

Exclusion Criteria:

1. Has any condition or circumstance, which in the opinion of the Investigator would significantly interfere with the subject's protocol compliance or put the subject at increased risk.
2. Unable or unwilling to provide written, signed, and dated informed consent to participate in the study.
3. Has undergone a second organ transplant with an organ derived from an individual other than the donor of the transplant kidney received during a Medeor study.
Bright Light Therapy for Individuals With Dementia

Many older adults with dementia living in long-term care facilities experience depression and agitation, which cause angst and personal suffering. Prior to this research, evidence was inconclusive but indicated that bright light exposure may reduce depression and agitation in long-term care residents with dementia. The purpose of this study was to determine if the degree of improvement in depression and agitation scores over the course of eight weeks was significantly greater in persons with dementia receiving bright light exposure than in persons with dementia receiving placebo light exposure. Sixty individuals participated in the study, with 30 in the bright light group and 30 in the low level light group.


Eligibility Criteria:
Inclusion criteria were age 60 or older; diagnosis of dementia; ophthalmology screening indicating that the individual was able to perceive light and did not have cataracts, glaucoma, macular degeneration, or retinal problems; able to sit up and keep eyes open; and not too restless to sit for 30 minutes.

Exclusion criteria were age 59 or younger; no diagnosis of dementia; presence of cataracts, glaucoma, macular degeneration, or retinal problems; unable to sit up and keep eyes open; and too restless to sit for 30 minutes.
Does Delaying Curative Surgery for Colorectal Cancer Influence Long-term Disease Free Survival.

This work is an original clinical research article describing the relationship between wait list tome for colorectal cancer patients and long-term survival. These findings are particularly relevant for management of surgical wait lists during crisis such as the Covid-19 pandemic. The lack of a relationship between wait list time and disease free survival and tendency for improved survival in the 4-6 week imply some colorectal cancer operations can be safely delayed during times of limited resources.

Background Surgical wait list time is a major problem in many health-care systems and its influence on survival is unclear. The aim of this study is to assess the impact of the wait list time on long term disease-free survival in patients scheduled for colorectal cancer resection.

Materials and Methods A prospective, single center study was carried out in patients with stage I-III colorectal cancer scheduled for surgery between 2012-2017 at a Colorectal Surgery Unit of a tertiary care center. Wait list time was defined as the time from completion of diagnostic workup and definitive surgery and divided into 2-week intervals from 2 to 6 weeks. The outcome variables were 2- and 5-year disease free survival. Screening for disease progression was with carcinoembryonic antigen levels and chest/abdominal computed tomography scan. Data was collected prospectively and subsequently analyzed.

Eligibility Criteria:
Inclusion Criteria:

* American Joint Committee on Cancer (AJCC) stage I through III confirmed adenocarcinomas
* With "colon" or "upper rectum" as their primary site of malignancy according to International Classification of Diseases for Oncology, Third Edition topography code.

Exclusion Criteria:

* Emergency surgery,
* More than one primary site,
* Synchronous metastasis or peritoneal carcinomatosis at the time of surgery
* If they received neoadjuvant chemoradiotherapy
* If they had a local transanal excision.
Effects of Preoperative Rehabilitation on Tendon Healing and Bone Mineral Density After ACLR

To explore the effect of preoperative exercise rehabilitation on bone mineral density, tendon bone healing, change of cartilage, and gait feature in patients with anterior cruciate ligament rupture.

Anterior Cruciate Ligament (ACL) injury is one of the most common sports injuries. It is a serious knee injury. The fracture of ACL can cause functional instability of knee joint, damage of meniscus and articular cartilage, and even induce knee osteoarthritis and other diseases. It has great influence on knee joint and even lower limb function of patients. Arthroscopic ACL reconstruction has become the first choice in clinical treatment of ACL fracture.

ACL fracture can cause local knee joint osteoporosis, and reconstruction surgery can also affect tendon bone healing, bone canal enlargement, rehabilitation period, gait, articular cartilage degradation, etc.

This study intends to conduct preoperative rehabilitation intervention for young people with anterior fork rupture, and explore the effects of exercise rehabilitation on knee bone mineral density, muscle strength, proprioceptive ability and other aspects after ACL rupture, as well as the effects of knee bone mineral density, tendon bone healing, bone tunnel aperture, motor function, gait characteristics and cartilage degradation after reconstruction.

Eligibility Criteria:
Inclusion Criteria:

1. Age 18\~40 years old, diagnosed ACL rupture by MRI;
2. The first unilateral ACL rupture requires reconstruction at our hospital;
3. Greater than 6 weeks from trauma and within 6 months.

Exclusion Criteria:

1. Be older than 40 years, or less than 18 years old
2. Within 8 weeks of the onset of the trauma, or more than 1 year
3. Severe injury to other knee ligaments
4. History of knee trauma